AAP
KPTI icon

Arax Advisory Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Arax Advisory Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-36
Closed -$447 – 2590
2024
Q3 		$447 Hold
36
– – ﹤0.01% 2416
2024
Q2 		$467 Buy
+36
New +$596 ﹤0.01% 2339

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Arax Advisory Partners's KPTI Position: Q4 2024 in Review

Arax Advisory Partners sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 36 shares — an estimated $447 sold.

Arax Advisory Partners first reported a position in KPTI in Q2 2024 and held it in 2 quarters. The position peaked at $467 in Q2 2024. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

  • Arax Advisory Partners reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 36 Karyopharm Therapeutics shares in Q4 2024, an estimated $447.
  • Arax Advisory Partners first reported a position in Karyopharm Therapeutics in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's Karyopharm Therapeutics position peaked at $467 in Q2 2024.
  • 87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.